Ahmedabad-based drugmaker Zydus Cadila and Hyderabad-based Dr Reddy's Laboratories said they have signed non-exclusive licensing pacts with US-based Gilead Sciences. This gives them the right to make and sell Gilead's investigational antiviral drug, Remdesivir, a potential treatment for COVID-19. They will be able to market the drug in 127 countries after getting necessary regulatory approvals.